Moderna's wider-than-expected loss and soft guidance weigh on battered stock
Portfolio Pulse from
Moderna reported a wider-than-expected loss and provided soft guidance, negatively impacting its stock. While COVID-19 vaccine sales exceeded expectations, RSV sales were modest.
February 14, 2025 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Moderna's stock is under pressure due to a wider-than-expected loss and soft future guidance. Despite COVID-19 vaccine sales surpassing expectations, RSV sales were modest, contributing to the negative sentiment.
The negative earnings report and soft guidance are likely to weigh on Moderna's stock in the short term. Although COVID-19 vaccine sales were strong, the modest RSV sales and overall financial performance are causing investor concern.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100